Genomics is helping improve diagnosis and treatment for heart patients
Genetic factors often play a role in the development of heart disease, making genetic testing an important tool in the fight against this deadly condition. Calgary-based biotechnology company, BioAro Inc., is committed to helping patients with heart disease as well as individuals who may be at higher risk of developing it.
As we recognize Heart Month, it's important to note that cardiovascular diseases continue to grow every year, affecting over three million Canadians, with over 750,000 Canadians living with heart failure. Additionally, more than 100,000 Canadians are diagnosed with heart failure annually, underscoring the urgent need for innovative solutions that can help identify and treat this life-threatening condition.
With its advanced genetic testing services, BioAro Inc. is leading the charge in precision-based medicine, enabling healthcare providers to develop personalized treatment plans that can address patients' unique risk factors and improve their outcomes. As we continue to raise awareness about the importance of heart health, BioAro's commitment to advancing the field of genomics and precision health is sure to play a critical role in helping individuals live longer, healthier lives.
